Pharvaris to Unveil Key Deucrictibant Data at EAACI Congress 2026
Event summary
- Pharvaris will present 8 abstracts at EAACI Annual Congress 2026, including one oral presentation and seven flash talk/poster presentations.
- Key data includes Phase 3 RAPIDe-3 trial results for deucrictibant immediate-release capsule in treating HAE attacks.
- Presentations cover cardiovascular safety, biomarker differentiation, and long-term safety/efficacy data.
- Topline data from CHAPTER-3 Phase 3 study expected in Q3 2026.
- CREAATE Phase 3 study for AAE-C1INH ongoing.
The big picture
Pharvaris is positioning itself as a key player in bradykinin-mediated angioedema treatment with its oral deucrictibant formulations. The upcoming data presentations come at a critical juncture as the company prepares marketing authorization applications and advances its pivotal Phase 3 studies. Success in these areas could significantly alter the HAE treatment landscape, potentially offering patients an effective oral alternative to injectable therapies.
What we're watching
- Regulatory Timing
- Whether Pharvaris can maintain its marketing authorization application timeline following these data presentations.
- Competitive Positioning
- How the deucrictibant data compares to existing HAE treatments in terms of efficacy and convenience.
- Pipeline Progress
- The pace at which the CHAPTER-3 and CREAATE studies advance toward potential approvals.
Related topics